The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Real-world experience: ide-cel for R/R multiple myeloma
Doris K. Hansen, MD, Moffitt Cancer Center, Tampa, FL, provides an overview of the real-world outcomes of patients with relapsed/refractory (R/R) multiple myeloma treated with standard of care idecabtagene vicleucel (ide-cel) under the commercial FDA label. Despite more patients being penta-refractory and less fit compared to the pivotal KarMMa trial (NCT03361748), safety and 30-day responses in the real-world setting are comparable to the clinical trial population. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
